Strategic Partnerships Leverage proven collaboration experience such as the CNS feasibility study with Takeda to position Prosetta as a partner for large pharma seeking novel modalities. The Prosetta Paradigm offers access to first-in-class and best-in-class molecules via licensing or co-development, spanning infectious disease, oncology, and neurodegeneration, with global discovery execution through the India subsidiary.

Infectious Disease Focus Target opportunities in pan-family antivirals, antifungals, and next-generation antibiotics addressing antimicrobial resistance, aligning with major pharma and government programs seeking new antimicrobial assets and rapid deployment through Prosetta's protein assemblies targeting approach.

Global Discovery Highlight the ability to run discovery programs globally through a US base and a wholly owned India subsidiary, enabling cost-effective, scalable R&D collaborations and potential nearshore/offshore models attractive to partners seeking flexible development footprints.

Early Stage Readiness Emphasize the company's demonstrated ability to execute deals and its nimble, mid-sized team ready for licensing, option, or co-development agreements with large pharma or biotech partners, reducing risk for collaborators by leveraging platform validation.

Technology Differentiation Position protein assemblies as an underexploited biological layer with potential to unlock novel asset classes across multiple therapeutic areas, creating a unique selling point for partnering discussions and opportunities to license the platform or pursue joint ventures.